1. A method for operating a paint line having a plurality of modular manufacturing stations, comprising:
advancing at least one carrier from a beginning of the paint line to an end of the paint line along a transportation path in a forward transport direction; and
wherein the advancing step includes independently moving a first carrier of a first modular manufacturing station according to a first unique operation pattern relative to a piece of paint application equipment and a second carrier of a second modular manufacturing station according to a second unique operation pattern, and indexing the first and second carriers as each of the first and second carriers traverses to a contiguous modular manufacturing station.
2. The method of claim 1, wherein the step of independently moving the first carrier includes moving the first carrier in the forward transport direction and moving the first carrier in a reverse transport direction that is opposite the forward transport direction.
3. The method of claim 1, wherein the step of independently moving the first carrier includes moving the first carrier in a vertical direction relative to the transportation path.
4. The method of claim 1, wherein the indexing step includes detecting a position of the first carrier and detecting a position of the second carrier.
5. The method of claim 4, wherein the indexing step further includes simultaneously transferring the first carrier to the second modular manufacturing station, and transferring the second carrier to a third modular manufacturing station.
6. The method of claim 1, wherein the advancing step includes detecting a position of the first carrier and initiating movement of the first carrier according to the first unique operation pattern responsive to the detected position.
7. The method of claim 1, wherein the step of independently moving the first carrier includes transmitting a control signal from a main control system to a station control system of the first modular manufacturing station, and transmitting the control signal from the station control system to an article transportation device of the first modular manufacturing station.
8. The method of claim 7, wherein the step of independently moving the first carrier further includes moving the first carrier using an independent drive system of the article transportation device in response to the control signal.
9. The method of claim 8, wherein the step of independently moving the first carrier further includes supporting the first carrier on a trolley, and supporting the trolley on an independent carrier track of the article transportation device.
10. The method of claim 9, wherein the step of independently moving the first carrier further includes frictionally engaging the trolley with a spinning drive tube of the article transportation device, and rotating the spinning drive tube with the independent drive system.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A 5-HT3 receptor antagonist having at least one characteristic chosen from the group consisting of:
a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
e. the primary metabolites are soluble in water at physiological pH;
f. the primary metabolites have negligible inhibitory activity at the IKR (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone.
2. The compound, according to claim 1, wherein said compound has the following structure, or is an analog or a salt of a compound having the following structure:
1
XN, or CH
Rlower alkyl optionally substituted with OH or NH2.
3. The compound, according to claim 2, having the following formula:
2
XN, or CH
Rlower alkyl optionally substituted with OH or NH2.
4. The compound, according to claim 1, wherein said compound has the following structure, or is an analog or a salt of a compound having the following structure::
3
XCH, or N
Y(CH2)n
Rlower alkyl optionally substituted with OH or NH2.
5. The compound, according to claim 4, having the following structure:
4
XCH, or N
Y(CH2)n
Rlower alkyl optionally substituted with OH or NH2.
6. The compound, according to claim 1, wherein said compound has the following structure, or is an analog or a salt of a compound having the following structure:
5
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
7. The compound, according to claim 6, having the following structure:
6
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
8. A pharmaceutical composition comprising a 5-HT3 receptor antagonist having at least one characteristic chosen from the group consisting of:
a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
e. the primary metabolites are soluble in water at physiological pH;
f. the primary metabolites have negligible inhibitory activity at the IKR (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone;
wherein said composition further comprises a pharmaceutical carrier.
9. The pharmaceutical composition, according to claim 8, comprising a compound, or an analog or salt thereof, wherein said compound has the following structure:
7
XN, or CH
Rlower alkyl optionally substituted with OH or NH2.
10. The composition, according to claim 10, comprising a compound having the following structure:
8
XN, or CH
Rlower alkyl optionally substituted with OH or NH2.
11. The composition, according to claim 8, comprising a compound or an analog or salt thereof, wherein said compound has the following structure:
9
XCH, or N
Y(CH2) n
Rlower alkyl optionally substituted with OH or NH2.
12. The composition, according to claim 11, comprising a compound having the following structure:
10
XCH, or N
Y(CH2)n
Rlower alkyl optionally substituted with OH or NH2.
13. The composition, according to claim 1, comprising a compound, or an analog or salt thereof, wherein said compound has having the following structure:
11
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
14. The composition, according to claim 13, comprising a compound having the following structure:
12
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
15. A method for blocking 5-HT3 activity in a patient in need of such treatment wherein said method comprises administering to said patient a 5-HT3 blocking compound having at least one of the following characteristics:
a. the compound is metabolized both by CYP450 and by a non-oxidative metabolic enzyme or system of enzymes;
b. the compound has a short (up to four (4) hours) non-oxidative metabolic half-life;
c. the compound contains a hydrolysable bond that can be cleaved non-oxidatively by hydrolytic enzymes;
d. the primary metabolites of the compound result from the non-oxidative metabolism of the compound;
e. the primary metabolites are soluble in water at physiological pH;
f. the primary metabolites have negligible inhibitory activity at the IKR (HERG) channel at normal therapeutic concentration of the parent drug in plasma;
g. the compound, as well as the metabolites thereof, does not cause metabolic DDI when co-administered with other drugs; and
h. the compound, as well as metabolites thereof, does not elevate LFT values when administered alone.
16. The method, according to claim 15, comprising administering a compound, or an analog or salt thereof, wherein said compound has the following structure:
13
XN, or CH
Rlower alkyl optionally substituted with OH or NH2.
17. The method, according to claim 16, wherein said compound has the following formula:
14
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
18. The method, according to claim 15, comprising administering a compound, or an analog or salt thereof, wherein said compound has the following structure:
15
XCH, or N
Y(CH2)n
Rlower alkyl optionally substituted with OH or NH2.
19. The method, according to claim 18, wherein said compound has the following structure:
16
XCH, or N
Y(CH2)n
Rlower alkyl optionally substituted with OH or NH2.
20. The method, according to claim 15, comprising administering a compound, or an analog or salt thereof, wherein said compound has the following structure:
17
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
21. The method, according to claim 20, wherein said compound has the following structure:
18
XCH, or N
Rlower alkyl optionally substituted with OH or NH2.
22. The method, according to claim 15, wherein the patient is human.
23. The method, according to claim 15, wherein said method is used to treat irritable bowel syndrome.